论文部分内容阅读
Acute myocardial infarction (AMI) is a main threat to human lives worldwide.Early and accurate diagnoses warrant immediate medical care,which would reduce mortality and improve prognoses.Circulating non-coding RNAs have been demonstrated to serve as competent biomarkers for various diseases.Following the identification of cardiac-specific microRNA miR-208a in circulation,more non-coding RNAs (miR-1,miR-499 and miR-133) have been identified as biomarkers not only for the diagnosis of AMI but also for prognosis post infarction.Here,we summarized recent findings on non-coding RNAs as biomarkers for early diagnosis of ST-segment elevation myocardial infarction and for disease monitoring of myocardial infarction.In addition,the prognostic potential of non-coding RNAs in patients treated with percutaneous coronary intervention was also described.We also include studies based on biobanks,and build a miRNA release spectrum after AMI,which provides quantitative and time-lapse monitoring of AMI progress.With this spectrum,we are able to customize personal medical care,which prevents further damage.By constructing a network of circulating non-coding.RNAs with high specificity and sensitivity,detailed diagnostic information was provided for personalized medicine.Unveiling the roles and kinetics of circulating non-coding RNAs may lead to a revolution in clinical diagnosis.